Drug intelligence / Profile preview

META-11-PH

Development stage: Preclinical
Lead developer: META Pharmaceuticals
Modality: Small Molecules

Overview

META-11-PH is one of three first-in-class small molecule inhibitors under development by META Pharmaceuticals, a China-based biotech company. The drug is being developed to address significant unmet medical needs in autoimmune diseases by utilizing an innovative approach that integrates cutting-edge immunometabolism research with artificial intelligence.

Beyond the preview

Go deeper on META-11-PH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on META-11-PH.

Explore the full profile